BIOCAD as knowledge-based company is focused on the technology know-how and research and development capabilities.
With the biosimilars and innovative products in portfolio BIOCAD is turned to fast growing foreign economies as well as to well established markets.
BIOCAD is open to cooperation with significant synergy potential and a view to robust expansion of international markets based on mutual benefits. Understanding the complexity of the challenges we face, we stay within our core competencies, and we use all opportunities from our related knowledge. We do this by strengthening our own research and development activities, and by actively working with our colleagues – scientists, doctors, and pharmacists.
all fields with an * are required
BIOCAD invites new partners to join its R&D programs through co-development of innovative molecules. BIOCAD has a number of unique products in various stages of development for treatment of oncological and autoimmune diseases. Co-development projects will increase the value of the partners' product portfolios and combine talents from various parts of the world.
BIOCAD aspires to advance its products in the international markets through partnerships with local pharmaceutical companies and distributors, by providing support for regulatory approval and commercialization of the products in each territory.
BIOCAD is willing to share its experience and knowledge in mAb manufacturing processes. With a tried and tested technology, standards of operational management, highly demanded products, effective system of staff training, as well as franchisor’s support and expertise, risks are minimized throughout all project stages. Our proven business concept guarantees short payback periods, high rates of return, and stable revenue flows. For more details click here